Allergic Rhinitis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Allergic Rhinitis – Pipeline Review, H2 2017’, provides an overview of the Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis

The report reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Allergic Rhinitis therapeutics and enlists all their major and minor projects

The report assesses Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Allergic Rhinitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Accolade Pharmaceuticals LLC

AFFiRiS AG

ALK-Abello A/S

AlleCures Inc

Allergy Therapeutics Plc

ASIT Biotech SA

Axikin Pharmaceuticals Inc

Chong Kun Dang Pharmaceutical Corp

Chrysalis BioTherapeutics Inc

Fountain Biopharma Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

HAL Allergy BV

Hisamitsu Pharmaceutical Co Inc

Intrommune Therapeutics

J Uriach Y Compania SA

Laboratorios LETI SL

Paradigm Biopharmaceuticals Ltd

Sanofi

Stallergenes Greer plc

Sun Pharma Advanced Research Company Ltd

Taiho Pharmaceutical Co Ltd

Therabron Therapeutics Inc

Xencor Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Allergic Rhinitis - Overview 7

Allergic Rhinitis - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 18

Allergic Rhinitis - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Allergic Rhinitis - Companies Involved in Therapeutics Development 27

Accolade Pharmaceuticals LLC 27

AFFiRiS AG 27

ALK-Abello A/S 27

AlleCures Inc 28

Allergy Therapeutics Plc 29

ASIT Biotech SA 29

Axikin Pharmaceuticals Inc 30

Chong Kun Dang Pharmaceutical Corp 30

Chrysalis BioTherapeutics Inc 30

Fountain Biopharma Inc 31

GlaxoSmithKline Plc 31

Glenmark Pharmaceuticals Ltd 32

HAL Allergy BV 32

Hisamitsu Pharmaceutical Co Inc 33

Intrommune Therapeutics 33

J Uriach Y Compania SA 34

Laboratorios LETI SL 34

Paradigm Biopharmaceuticals Ltd 34

Sanofi 35

Stallergenes Greer plc 35

Sun Pharma Advanced Research Company Ltd 36

Taiho Pharmaceutical Co Ltd 36

Therabron Therapeutics Inc 37

Xencor Inc 37

Allergic Rhinitis - Drug Profiles 39

(fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile 39

(mometasone furoate + olopatadine hydrochloride) - Drug Profile 40

854-A - Drug Profile 41

Allergen for Allergic Conjunctivitis and Allergic Rhinitis - Drug Profile 42

Allergen for Allergic Rhinitis - Drug Profile 43

Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile 44

Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 45

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile 46

Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile 47

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 48

Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 49

Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 50

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 52

Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 53

arabinogalactan - Drug Profile 54

B-244 - Drug Profile 55

bepotastine besilate SR - Drug Profile 57

BM-41 - Drug Profile 58

CBP-174 - Drug Profile 59

CG-201 - Drug Profile 60

CPC-888 - Drug Profile 61

emedastine difumarate - Drug Profile 62

FB-825 - Drug Profile 63

gp-ASIT - Drug Profile 64

GSK-2245035 - Drug Profile 68

hdm-ASIT - Drug Profile 69

KR-62980 - Drug Profile 71

Lactococcus lactis G121 - Drug Profile 72

levocabastine hydrochloride + mometasone furoate - Drug Profile 73

mometasone furoate - Drug Profile 74

Monoclonal Antibody for Seasonal Allergic Rhinitis - Drug Profile 75

nasapaque - Drug Profile 76

NVP-1703 - Drug Profile 77

pentosan polysulfate sodium - Drug Profile 78

Pollinex Quattro Tree - Drug Profile 82

rag-ASIT - Drug Profile 84

rupatadine - Drug Profile 85

short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT - Drug Profile 86

Small Molecule for Allergic Rhinitis - Drug Profile 87

Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile 88

Small Molecules for Respiratory Disorders - Drug Profile 89

Small Molecules for Seasonal Allergic Rhinitis - Drug Profile 90

Small Molecules to Antagonize H1 and H3 Receptor for Allergic Rhinitis - Drug Profile 91

Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile 92

standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile 93

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 96

STG-120 - Drug Profile 101

SUN-0597 - Drug Profile 102

SYM-001 - Drug Profile 104

TAS-205 - Drug Profile 105

TO-206 - Drug Profile 106

Vaccine for Asthma and Allergic Rhinitis - Drug Profile 107

Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile 108

XmAb-7195 - Drug Profile 109

Zafi-3 - Drug Profile 111

Allergic Rhinitis - Dormant Projects 112

Allergic Rhinitis - Discontinued Products 119

Allergic Rhinitis - Product Development Milestones 121

Featured News & Press Releases 121

Appendix 130

Methodology 130

Coverage 130

Secondary Research 130

Primary Research 130

Expert Panel Validation 130

Contact Us 130

Disclaimer 131

List of Tables

List of Tables

Number of Products under Development for Allergic Rhinitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Allergic Rhinitis – Pipeline by Accolade Pharmaceuticals LLC, H2 2017

Allergic Rhinitis – Pipeline by AFFiRiS AG, H2 2017

Allergic Rhinitis – Pipeline by ALK-Abello A/S, H2 2017

Allergic Rhinitis – Pipeline by AlleCures Inc, H2 2017

Allergic Rhinitis – Pipeline by Allergy Therapeutics Plc, H2 2017

Allergic Rhinitis – Pipeline by ASIT Biotech SA, H2 2017

Allergic Rhinitis – Pipeline by Axikin Pharmaceuticals Inc, H2 2017

Allergic Rhinitis – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017

Allergic Rhinitis – Pipeline by Chrysalis BioTherapeutics Inc, H2 2017

Allergic Rhinitis – Pipeline by Fountain Biopharma Inc, H2 2017

Allergic Rhinitis – Pipeline by GlaxoSmithKline Plc, H2 2017

Allergic Rhinitis – Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017

Allergic Rhinitis – Pipeline by HAL Allergy BV, H2 2017

Allergic Rhinitis – Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2017

Allergic Rhinitis – Pipeline by Intrommune Therapeutics, H2 2017

Allergic Rhinitis – Pipeline by J Uriach Y Compania SA, H2 2017

Allergic Rhinitis – Pipeline by Laboratorios LETI SL, H2 2017

Allergic Rhinitis – Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017

Allergic Rhinitis – Pipeline by Sanofi, H2 2017

Allergic Rhinitis – Pipeline by Stallergenes Greer plc, H2 2017

Allergic Rhinitis – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Allergic Rhinitis – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017

Allergic Rhinitis – Pipeline by Therabron Therapeutics Inc, H2 2017

Allergic Rhinitis – Pipeline by Xencor Inc, H2 2017

Allergic Rhinitis – Dormant Projects, H2 2017

Allergic Rhinitis – Dormant Projects, H2 2017 (Contd..1), H2 2017

Allergic Rhinitis – Dormant Projects, H2 2017 (Contd..2), H2 2017

Allergic Rhinitis – Dormant Projects, H2 2017 (Contd..3), H2 2017

Allergic Rhinitis – Dormant Projects, H2 2017 (Contd..4), H2 2017

Allergic Rhinitis – Dormant Projects, H2 2017 (Contd..5), H2 2017

Allergic Rhinitis – Dormant Projects, H2 2017 (Contd..6), H2 2017

Allergic Rhinitis – Discontinued Products, H2 2017

Allergic Rhinitis – Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

List of Figures

Number of Products under Development for Allergic Rhinitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports